

# Contents

<i>Preface</i>	xi
<b>SECTION I</b>	
<b>1 Nanomedicine: The Dawn of a New Era</b>	<b>3</b>
<i>Mario Ganau, Marco Paris, Nicola Nicassio, and Gianfranco K. Ligarotti</i>	
1.1 Facts and Forecasts	3
1.2 Aims of Nanomedicine	6
1.2.1 Improving Diagnostic Tools	7
1.2.2 Improving Drug Delivery	9
1.2.3 Improving Surgical Strategies	12
1.3 Organizations and Open Projects	14
<b>2 Diagnostic Challenges of Nanomedicine</b>	<b>21</b>
<i>Mario Ganau, Alessandro Bosco, Pietro Parisse, and Loredana Casalis</i>	
2.1 Beyond Conventional Diagnostics	21
2.2 Miniaturization and Functionalization Techniques	23
2.2.1 Conventional Photolithography and Beyond	24
2.2.2 Micro- and Nanocontact Printing	27
2.2.3 Dip-Pen Nanolithography	29
2.2.4 AFM Nanografting	30
2.3 Evolution of Biosensors for Diagnostics	33
2.3.1 Optical Readout	34
2.3.2 Radiolabeled Readout	36
2.3.3 Mass Detection Readout	37
2.3.4 Mechanical-Sensing Readout	39
2.3.5 DNA-Directed Immobilization	40

2.4	In vitro Diagnostics	41
2.4.1	Trends in Single-Cell DNA Barcode Analysis	42
2.4.2	Trends in Carbon Nanotubes and Their Use in Microfluidic Devices	44
2.5	In vivo Diagnostics	46
2.5.1	Implantable Devices	46
2.5.2	Improvements in Conventional Radiology	48
2.6	Future Trends	49
<b>3</b>	<b>Surgery in the Realm of Nanometers</b>	<b>59</b>
	<i>Mario Ganau, Roberto Israel Foroni, and Rossano Ambu</i>	
3.1	Introduction	59
3.2	Potential Implications in the Field of Nanotechnology and Regenerative Medicine	60
3.2.1	Nanomaterials	60
3.2.2	Next Generation's Prostheses	62
3.2.3	Gene Therapy and Surgical Procedures	64
3.2.4	Preventing Postoperative Fibrosis and Excessive Cicatrization	65
3.3	Cellular and Subcellular Surgical Procedures	66
3.3.1	Design Improvements of Nanosurgical Instruments	68
3.4	Nanorobotics	69
3.4.1	Miniaturized Propelling Systems	70
3.4.2	Artificial Cells	71
3.5	Brain–Machine Interfaces	73
3.6	Conclusions	75
<b>4</b>	<b>Nanotherapeutics</b>	<b>81</b>
	<i>Julielynn Wong</i>	
4.1	Introduction	81
4.2	Biological, Physical, and Chemical Properties and Pharmacological Effects of Nanotherapeutics	82
4.3	Nanoformulations	85
4.3.1	Nanoemulsions	85
4.3.2	Liposomes	87
4.3.3	Micelles	88
4.3.4	Nanogels	88

4.3.5	Dendrimers	89
4.3.6	Polymer Conjugates	90
4.3.7	Gold Nanoparticles	91
4.3.8	Magnetic Nanoparticles	93
4.3.9	Improved Cancer Therapies with Nanobased Drug Carriers	93
4.3.10	Encapsulating Nanovaccines	94
4.3.11	Nanobead Vaccines	95
4.3.12	Micronanoprojection Vaccines	95
4.3.13	Combined Design Approaches for Nanovaccines	95
4.4	Commercial Advantages of Nanoformulated Agents	96
4.5	Nanomedicine Publications, Patents, Product Development, and Companies	96
4.6	Current Challenges and Priorities	97
4.7	Nanotoxicity	98
4.8	Future Trends	99
<b>SECTION II</b>		
<b>5</b>	<b>Ethics and Nanoethics</b>	<b>111</b>
	<i>Mario Ganau, Lara Prisco, and Laura Ganau</i>	
5.1	Introduction	111
5.2	Learning from Our Past	112
5.3	Utopian Promises, Dystopian Fears	113
5.4	Development Regulations	114
5.5	Evolving Our Nature	115
5.6	Conclusions	116
<b>6</b>	<b>Nanomedicine Policy and Regulation Schemes</b>	<b>119</b>
	<i>Sarah Rouse Janosik</i>	
6.1	Overview	119
6.2	Standardization of Nanotechnology Terminology and Characterization Methodologies	120
6.2.1	Standardization of Nanomedicine Terminology	121
6.2.2	Standardization Organizations	122
6.2.2.1	ASTM International Committee E56	122
6.2.2.2	ISO/TR 12802:2010	123

6.2.3	Standardization through Patent Systems	123
6.2.4	Physicochemical Characterization of Nanomedical Compounds and Devices	124
6.3	Regulation of Nanomedicine	124
6.3.1	US Food and Drug Administration	124
6.3.2	US Environmental Protection Agency and US Consumer Product Safety Commission	125
6.3.3	European Medicines Agency	126
6.3.4	Health Canada	127
6.4	Conclusion	128
<b>SECTION III</b>		
<b>7</b>	<b>Overview of Intellectual Property Rights</b>	<b>135</b>
	<i>Wim Helwegen and Luca Escoffier</i>	
7.1	Patents	136
7.1.1	Requirements	136
7.1.1.1	Patentable subject matter	137
7.1.1.2	Novelty	138
7.1.1.3	Industrial application/utility	139
7.1.1.4	Inventive step/nonobviousness	140
7.1.1.5	Disclosure	140
7.1.2	Postgrant	142
7.1.3	Exempted Uses	143
7.2	Other forms of Intellectual Property	144
7.2.1	Utility Models	144
7.2.2	Copyright	145
7.2.2.1	Economic rights, moral rights, and other features	146
7.2.3	Trademarks	146
7.2.3.1	Requirements and characteristics	147
7.2.4	Industrial Designs	148
7.3	Trade Secrets	148
<b>8</b>	<b>IP Valuation: Principles and Applications in the Nanotechnology Industry</b>	<b>151</b>
	<i>Efrat Kasznik</i>	
8.1	Overview of IP Valuation	151

8.1.1	What Is Intellectual Property Valuation?	151
8.1.1.1	Brief history of IP valuation in the United States	151
8.1.1.2	IP valuation methodologies	152
8.1.1.3	Types of intangible assets	153
8.1.2	IP Valuation Standards in the United States	154
8.1.2.1	IP valuation landscape in the United States	154
8.1.2.2	IP valuation for litigation damages	155
8.1.2.3	IP valuation for financial reporting	157
8.1.2.4	IP valuation for tax reporting	159
8.1.3	IP Valuation Circumstances in Europe	160
8.1.3.1	Litigation damages	160
8.1.3.2	Financial reporting	161
8.1.3.3	Tax reporting	161
8.2	The Application of IP Valuation in the Nanotechnology Industry	162
8.2.1	IP Valuation vs. Evaluation	162
8.2.2	Valuing an IP portfolio in the Nanotechnology Industry	163
8.2.2.1	Patenting along the value chain	163
8.2.2.2	Technology transfer from university to industry	164
8.2.2.3	Mitigating litigation risk	165
<b>9</b>	<b>Commercialization, Valuation, and Evaluation of Nanotech Innovations</b>	<b>169</b>
	<i>Luca Escoffier</i>	
9.1	The Commercialization of Nanotechnology Innovations	169
9.2	Cost, Price, and Value: Patent Valuation vs. Patent Evaluation	176
9.2.1	Patent Valuation	178
9.2.1.1	Cost approach	180
9.2.1.2	Market approach	181
9.2.1.3	Income approach	182
9.2.2	Patent Evaluation	184
9.2.2.1	Market	184

9.2.2.2	Regulatory and legal issues	185
9.2.2.3	Technology	185
9.2.2.4	Financing	186
9.3	Introducing a Novel Approach: "Present Value After Evaluation"	187
9.4	Conclusions	204
	<i>Notes on the Contributors</i>	213